Startups.Bio showcases an emerging biotech startup each week, selected by the analyst team at VentureRadar from the 10,000s of companies we track.
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation and mutations. Transcription factors (TFs) have long been the aspirational targets of drug developers, based on their central role in cancer and other diseases. TFs are DNA-binding proteins that can […]
Shoreline Biosciences is developing genetically engineered induced pluripotent stem cell (iPSC)-derived allogeneic natural killer (NK) and macrophage cellular immunotherapies that are intelligently designed for greater potency and persistence, to create safe, effective, and affordable immunotherapies for the treatment of seriously ill patients. Shoreline’s proprietary cell therapy platform is based on deep expertise in iPSC differentiation […]
Exo Therapeutics leverages its ExoSite™ platform to develop a deep pipeline of potent drug candidates that bind exosites – distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Enzymes play key roles in all metabolic processes, such as destroying toxins and aiding digestion. This critical […]